Spatial distribution of insulin-like growth factor binding protein-2 following hypoxic-ischemic injury

BMC Neuroscience

Murat Digicaylioglu²  David F Jimenez¹  Betty B Alajajian¹  Lindsey H Williams³  Shane Sprague¹  Elif Isgor¹  Lauren Fletcher¹ 

[1]Department of Neurosurgery, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA

[2]Department of Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA

[3]School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA

关键词: Intranasal administration;    Insulin-like growth factor-I;    Insulin-like growth factor binding protein-2;    Neuroprotection;    Ischemia;    Stroke;   

Others  :  1122667
DOI  :  10.1186/1471-2202-14-158

 received in 2012-12-18, accepted in 2013-12-10,  发布年份 2013

【 摘 要 】

Background

Insulin-like growth factor binding protein-2 (IGFBP-2) regulates the bioavailability, transportation, and localization of insulin-like growth factor-I (IGF-I), an effective neuroprotectant in animal stroke models especially when administered intranasally. Therefore, determining IGFBP-2′s endogenous distribution in the normal and ischemic brain is essential in maximizing the neuroprotective potential of the intranasal IGF-I treatment approach. However, current data on IGFBP-2 is limited to mRNA and in situ hybridization studies. The purpose of this study was to determine if there are any changes in IGFBP-2 protein levels and distribution in ischemic brain and also to determine if IGFBPs play a role in the transportation of intranasally administered IGF-I into the brain.

Results

Using an in vitro approach, we show that ischemia causes changes in the distribution of IGFBP-2 in primary cortical neurons and astrocytes. In addition, we show using the transient middle cerebral artery occlusion (MCAO) model in mice that there is a significant increase in IGFBP-2 levels in the stroke penumbra and core after 72 h. This correlated with an overall increase in IGF-I after stroke, with the highest levels of IGF-I in the stroke core after 72 h. Brain sections from stroke mice indicate that neurons and astrocytes located in the penumbra both have increased expression of IGFBP-2, however, IGFBP-2 was not detected in microglia. We used binding competition studies to show that intranasally administered exogenous IGF-I uptake into the brain is not receptor mediated and is likely facilitated by IGFBPs.

Conclusions

The change in protein levels indicates that IGFBP-2 plays an IGF-I-dependent and -independent role in the brain’s acute (neuroprotection) and chronic (tissue remodeling) response to hypoxic-ischemic injury. Competition studies indicate that IGFBPs may have a role in rapid transportation of exogenous IGF-I from the nasal tissue to the site of injury.

【 授权许可】

   
2013 Fletcher et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Iadecola C, Anrather J: Stroke research at a crossroad: asking the brain for directions. Nat Neurosci 2011, 14(11):1363-1368.
• [2]Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda MV, Olson DM, Hernandez AF, Peterson ED, Schwamm LH: Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation 2011, 123(7):750-758.
• [3]Fletcher L, Kohli S, Sprague SM, Scranton RA, Lipton SA, Parra A, Jimenez DF, Digicaylioglu M: Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. J Neurosurg 2009, 111(1):164-170.
• [4]Liu XF, Fawcett JR, Thorne RG, DeFor TA, Frey WH 2nd: Intranasal administration of insulin-like growth factor-I bypasses the blood–brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci 2001, 187(1–2):91-97.
• [5]Liu XF, Fawcett JR, Thorne RG, Frey WH 2nd: Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion. Neurosci Lett 2001, 308(2):91-94.
• [6]Belayev L, Busto R, Zhao W, Fernandez G, Ginsberg MD: Middle cerebral artery occlusion in the mouse by intraluminal suture coated with poly-L-lysine: neurological and histological validation. Brain Res 1999, 833(2):181-190.
• [7]Lo EH, Singhal AB, Torchilin VP, Abbott NJ: Drug delivery to damaged brain. Brain Res Brain Res Rev 2001, 38(1–2):140-148.
• [8]Hanson LR, Frey WH, Hanson LR, Frey WH II: Intranasal delivery bypasses the blood–brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008, 9(3):S5.
• [9]Danielyan L, Schafer R, von Ameln-Mayerhofer A, Buadze M, Geisler J, Klopfer T, Burkhardt U, Proksch B, Verleysdonk S, Ayturan M, et al.: Intranasal delivery of cells to the brain. Eur J Cell Biol 2009, 88(6):315-324.
• [10]Balin BJ, Broadwell RD, Salcman M, el-Kalliny M: Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol 1986, 251(2):260-280.
• [11]Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd: Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004, 127(2):481-496.
• [12]Guan J, Bennet L, Gluckman PD, Gunn AJ: Treatment in animal models. Endocr Dev 2005, 9:31-43.
• [13]Russo VC, Gluckman PD, Feldman EL, Werther GA: The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev 2005, 26(7):916-943.
• [14]Federico G, Maremmani C, Cinquanta L, Baroncelli GI, Fattori B, Saggese G: Mucus of the human olfactory epithelium contains the insulin-like growth factor-I system which is altered in some neurodegenerative diseases. Brain Res 1999, 835(2):306-314.
• [15]Suzuki Y, Takeda M: Expression of insulin-like growth factor family in the rat olfactory epithelium. Anat Embryol (Berl) 2002, 205(5–6):401-405.
• [16]Guan J, Williams CE, Skinner SJ, Mallard EC, Gluckman PD: The effects of insulin-like growth factor (IGF)-1, IGF-2, and des-IGF-1 on neuronal loss after hypoxic-ischemic brain injury in adult rats: evidence for a role for IGF binding proteins. Endocrinology 1996, 137(3):893-898.
• [17]Jones JI, Clemmons DR: Insulin-like growth-factors and their binding-proteins - biological actions. Endocr Rev 1995, 16(1):3-34.
• [18]Chesik D, De Keyser J, Wilczak N: Insulin-like growth factor binding protein-2 as a regulator of IGF actions in CNS: Implications in multiple sclerosis. Cytokine Growth Factor Rev 2007, 18(3–4):267-278.
• [19]Bondy CA, Cheng CM: Signaling by insulin-like growth factor 1 in brain. Eur J Pharmacol 2004, 490(1–3):25-31.
• [20]Gluckman P, Klempt N, Guan J, Mallard C, Sirimanne E, Dragunow M, Klempt M, Singh K, Williams C, Nikolics K: A role for Igf-1 in the rescue of Cns neurons following hypoxic-ischemic injury. Biochem Biophys Res Commun 1992, 182(2):593-599.
• [21]Klempt ND, Klempt M, Gunn AJ, Singh K, Gluckman PD: Expression of insulin-like growth factor-binding protein 2 (IGF-BP 2) following transient hypoxia-ischemia in the infant rat brain. Brain Res Mol Brain Res 1992, 15(1–2):55-61.
• [22]Beilharz EJ, Russo VC, Butler G, Baker NL, Connor B, Sirimanne ES, Dragunow M, Werther GA, Gluckman PD, Williams CE, et al.: Co-ordinated and cellular specific induction of the components of the IGF/IGFBP axis in the rat brain following hypoxic-ischemic injury. Brain Res Mol Brain Res 1998, 59(2):119-134.
• [23]O’Donnell SL, Frederick TJ, Krady JK, Vannucci SJ, Wood TL: IGF-I and microglia/macrophage proliferation in the ischemic mouse brain. Glia 2002, 39(1):85-97.
• [24]Fisher M: The ischemic penumbra: a new opportunity for neuroprotection. Cerebrovasc Dis 2006, 21(Suppl 2):64-70.
• [25]Wang L, Zhang Z, Wang Y, Zhang R, Chopp M: Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004, 35(7):1732-1737.
• [26]Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, Schellinger PD, Bohn M, Becker H, Wegrzyn M, et al.: Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009, 40(12):e647-e656.
• [27]Yamashita T, Deguchi K, Sawamoto K, Okano H, Kamiya T, Abe K: Neuroprotection and neurosupplementation in ischaemic brain. Biochem Soc Trans 2006, 34(Pt 6):1310-1312.
• [28]Carlsson-Skwirut C, Lake M, Hartmanis M, Hall K, Sara VR: A comparison of the biological activity of the recombinant intact and truncated insulin-like growth factor 1 (IGF-1). Biochim Biophys Acta 1989, 1011(2–3):192-197.
• [29]Crescioli C, Villari D, Forti G, Ferruzzi P, Petrone L, Vannelli GB, Adorini L, Salerno R, Serio M, Maggi M: Des (1–3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D3 analogue. Mol Cell Endocrinol 2002, 198(1–2):69-75.
• [30]Rotwein P, Burgess SK, Milbrandt JD, Krause JE: Differential expression of insulin-like growth factor genes in rat central nervous system. Proc Natl Acad Sci USA 1988, 85(1):265-269.
• [31]Andersson IK, Edwall D, Norstedt G, Rozell B, Skottner A, Hansson HA: Differing expression of insulin-like growth factor I in the developing and in the adult rat cerebellum. Acta Physiol Scand 1988, 132(2):167-173.
• [32]Werther GA, Abate M, Hogg A, Cheesman H, Oldfield B, Hards D, Hudson P, Power B, Freed K, Herington AC: Localization of insulin-like growth factor-I mRNA in rat brain by in situ hybridization–relationship to IGF-I receptors. Mol Endocrinol 1990, 4(5):773-778.
• [33]Guan J, Bennet L, Gluckman PD, Gunn AJ: Insulin-like growth factor-1 and post-ischemic brain injury. Prog Neurobiol 2003, 70(6):443-462.
• [34]Digicaylioglu M, Garden G, Timberlake S, Fletcher L, Lipton SA: Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Proc Natl Acad Sci USA 2004, 101(26):9855-9860.
• [35]Belayev L, Busto R, Zhao W, Ginsberg MD: Quantitative evaluation of blood–brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res 1996, 739(1–2):88-96.
• [36]Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ, Weber MM, Wolf E: Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res 2001, 61(24):8601-8610.
• [37]Mackay KB, Loddick SA, Naeve GS, Vana AM, Verge GM, Foster AC: Neuroprotective effects of insulin-like growth factor-binding protein ligand inhibitors in vitro and in vivo. J Cereb Blood Flow Metab 2003, 23(10):1160-1167.
• [38]Paciaroni M, Caso V, Agnelli G: The concept of ischemic penumbra in acute stroke and therapeutic opportunities. Eur Neurol 2009, 61(6):321-330.
• [39]Yao H, Yoshii N, Akira T, Nakahara T: Reperfusion-induced temporary appearance of therapeutic window in penumbra after 2 h of photothrombotic middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 2009, 29(3):565-574.
• [40]Zhu W, Fan Y, Frenzel T, Gasmi M, Bartus RT, Young WL, Yang GY, Chen Y: Insulin growth factor-1 gene transfer enhances neurovascular remodeling and improves long-term stroke outcome in mice. Stroke 2008, 39(4):1254-1261.
• [41]Ploughman M, Granter-Button S, Chernenko G, Attwood Z, Tucker BA, Mearow KM, Corbett D: Exercise intensity influences the temporal profile of growth factors involved in neuronal plasticity following focal ischemia. Brain Res 2007, 1150:207-216.
• [42]Hayakawa K, Nakano T, Irie K, Higuchi S, Fujioka M, Orito K, Iwasaki K, Jin G, Lo EH, Mishima K, et al.: Inhibition of reactive astrocytes with fluorocitrate retards neurovascular remodeling and recovery after focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2010, 30(4):871-882.
• [43]Yan YP, Lang BT, Vemuganti R, Dempsey RJ: Galectin-3 mediates post-ischemic tissue remodeling. Brain Res 2009, 1288:116-124.
• [44]Ekdahl CT, Kokaia Z, Lindvall O: Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience 2009, 158(3):1021-1029.
• [45]Li Y, Chen J, Zhang CL, Wang L, Lu D, Katakowski M, Gao Q, Shen LH, Zhang J, Lu M, et al.: Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. Glia 2005, 49(3):407-417.
• [46]Kooijman R, Sarre S, Michotte Y, De Keyser J: Insulin-like growth factor I: a potential neuroprotective compound for the treatment of acute ischemic stroke? Stroke 2009, 40(4):e83-e88.
• [47]Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH: Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003, 301(5634):839-842.
• [48]Kazanis I, Bozas E, Philippidis H, Stylianopoulou F: Neuroprotective effects of insulin-like growth factor-I (IGF-I) following a penetrating brain injury in rats. Brain Res 2003, 991(1–2):34-45.
• [49]Alajajian BB, Fletcher L, Isgor E, Jimenez DF, Digicaylioglu M: IGF-I regulated phosphorylation and translocation of PDK-1 in neurons. Neuroreport 2009, 20(6):579-583.
• [50]Zhao G, Flavin MP: Differential sensitivity of rat hippocampal and cortical astrocytes to oxygen-glucose deprivation injury. Neurosci Lett 2000, 285(3):177-180.
• [51]Kermer P, Digicaylioglu MH, Kaul M, Zapata JM, Krajewska M, Stenner-Liewen F, Takayama S, Krajewski S, Lipton SA, Reed JC: BAG1 over-expression in brain protects against stroke. Brain Pathol 2003, 13(4):495-506.